The results of such studies might be able to shed light on immunosuppressive signaling in human RCC and on how to select patients with tumors that are immune suppressed through the A2AR axis and who might respond to therapeutic blockade of this axis. The gene discussed is ADORA2A; the disease is renal cell carcinoma.